The historical limitations of tissue analysis

For decades, our ability to probe the intricate workings of biological tissues has been fundamentally limited. We could grind up tissue samples for bulk RNA sequencing, gaining deep transcriptomic insights but losing all sense of spatial organization, like analyzing a city’s economy by averaging data from every building, irrespective of whether it is a factory, home, or hospital. Alternatively, we could use immunohistochemistry (IHC) or immunofluorescence (IF) to visualize a handful of proteins in situ, preserving architecture but only capturing a tiny fraction of the molecular complexity. We know tissues were complex ecosystems, with several cell types interacting in specific sub-regions, but previous tools offered only blurred averages or narrow snapshots.

The rise of spatial biology

This gap between biological reality and analytical capability is closing. We are now firmly in the era of spatial biology, driven by revolutionary technologies that allow us to profile tissues with unprecedented molecular depth while crucially retaining spatial context. Leading this change in approach is multiplex immunohistochemistry/immunofluorescence (mIHC/mIF) and spatial transcriptomics, powerful approaches that are transforming how we understand health and disease at the tissue level.

Why traditional methods fell short

The limitations of traditional methods underscored the urgent need for innovation. Bulk RNA-seq, while powerful for identifying overall changes in gene expression, completely obscures cellular heterogeneity and spatial relationships. Crucial information about which cell type is expressing which genes, and where those cells reside relative to others, is lost in the average. Standard IHC/IF, a gold standard of pathology and tissue research for decades, typically allows visualization of only two to four protein markers simultaneously. While invaluable for confirming the presence and general location of specific proteins, this low plex level falls far short of capturing the intricate cellular compositions, activation states, and cell-cell interactions defining tissue function or dysfunction, particularly in complex environments like tumors or the brain.

Multiplex IHC/IF: Breaking the low-plex barrier

Multiplex IHC and immunofluorescence are techniques designed to counter the low-plex ceiling of traditional antibody-based staining. The core concept is powerful: visualize dozens, sometimes even 50 or more, protein markers simultaneously on a single tissue section. Various technological strategies achieve this feat. Some employ iterative cycles of staining with antibodies, imaging, and then stripping or quenching the signal before the next cycle (eg, CyCIF)¹. Others utilize antibodies conjugated to unique DNA barcodes or heavy metal isotopes, allowing simultaneous detection through specialized imaging or mass cytometry platforms (e.g., CODEX, MIBI)^2,3.

Applications in disease research

Regardless of the specific method, the result is transformative. We can now generate highly detailed maps of tissue architecture, identifying numerous cell types, subtypes, and functional states based on their unique protein expression signatures, all within their native spatial context. In cancer research, this allows for deep dissection of the tumor microenvironment (TME), precisely mapping the infiltration patterns of a range of immune cell subsets (T cells, B cells, macrophages, etc.), their proximity to cancer cells, and their activation status. This “immune contexture” is increasingly recognized as a critical determinant of patient prognosis and response to immunotherapy. Beyond cancer, mIHC/mIF is providing stunning insights into neuroinflammation, autoimmune lesions, and developmental processes.

Spatial transcriptomics: Mapping gene expression in situ

Complementing the protein-level view offered by mIHC/mIF is spatial transcriptomics. While mIHC tells us about the proteins present, spatial transcriptomics reveals the underlying genetic scripts being read, the gene expression profiles, across the tissue landscape. Unlike single-cell RNA-seq, which dissociates tissues and loses spatial information, spatial transcriptomics methods measure RNA levels while preserving their location.

Again, a range of approaches exists. Array-based methods, like the popular Visium platform, capture mRNA onto spatially barcoded spots on a slide, providing transcriptome-wide data for small regions across the section⁴. Imaging-based methods, such as MERFISH⁵, seqFISH, or Xenium, perform in situ sequencing or hybridization, directly detecting and counting hundreds or thousands of specific RNA molecules within individual cells, offering higher spatial resolution⁵.

Unlocking spatial gene expression patterns

The power of spatial transcriptomics lies in connecting gene expression signatures to specific subcellular locations, tissue structures, or cell populations. Researchers can identify transcriptionally distinct cellular neighbourhoods, discover novel spatially restricted gene expression patterns associated with disease states, or map developmental trajectories across a tissue section. It allows us to ask not just what genes are expressed, but precisely where and potentially in which cells.

The power of integration: Multi-omics spatial biology

Perhaps the most exciting frontier is the integration of these powerful technologies. By applying mIHC/mIF and spatial transcriptomics, often on the same or adjacent tissue sections, researchers can achieve a truly multi-omics spatial understanding. High-plex protein data can precisely define cell types, boundaries, and functional states, providing invaluable annotation for the accompanying spatial transcriptomics data. Conversely, spatial transcriptomics can reveal the transcriptional programs underlying observed protein expression patterns or cell-cell interactions identified by mIHC/mIF. This synergy provides a much richer, more holistic view than either modality alone, allowing us to connect genotype to phenotype within the complex spatial organization of tissues.

The impact of these technologies is already being shown across biomedical research. In oncology, they are revolutionizing our understanding of the TME, identifying potential biomarkers for immunotherapy response, and illuminating mechanisms of therapeutic resistance driven by specific spatial niches^6,7. Immunologists are using them to map intricate immune cell interactions in lymphoid organs, sites of infection, and autoimmune diseases with unprecedented granularity⁸. In neuroscience, these tools are essential for deciphering complex neural circuitry, understanding cellular diversity in different brain regions, and studying the spatial dynamics of neurodegeneration^9.10. Developmental biologists have tracked cell fate decisions and tissue patterning with spatially resolved gene and protein expression atlases¹¹.

Of course, harnessing the power of these cutting-edge technologies comes with challenges. The experimental workflows can be complex and costly. The sheer volume and complexity of the data generated necessitate sophisticated computational expertise for analysis, visualization, and interpretation. Integrating data from different spatial modalities remains a significant bioinformatics challenge. Furthermore, standardization of protocols and analytical methods is crucial for ensuring reproducibility and facilitating comparisons across studies.

Despite these hurdles, the trajectory is clear. Future developments promise even higher plex levels (more markers/genes), improved spatial resolution (true single-cell or even subcellular), streamlined workflows, and more powerful, user-friendly analytical tools. The push towards clinical translation, particularly using spatial biomarkers to guide patient stratification and treatment decisions, is also gaining momentum.

Conclusions and future directions

In conclusion, multiplex imaging and spatial transcriptomics represent a fundamental shift in how we study biological tissues. They allow us to move beyond dissociated cells or low-plex snapshots and begin appreciating tissues as the complex, spatially organized systems they truly are. By providing multi-layered molecular information within intact architectural context, these technologies are unlocking new insights into virtually every aspect of biology and medicine. For researchers seeking to understand the intricate interplay of cells that defines health and disease, the era of spatial biology is already here, and it is transforming the landscape of discovery.

Related resources

References

1.      Sheng W, Zhang C, Mohiuddin TM, Al-Rawe M, Zeppernick F, Falcone FH, Meinhold-Heerlein I, Hussain AF. Multiplex Immunofluorescence: A Powerful Tool in Cancer Immunotherapy. Int J Mol Sci. 2023 Feb 4;24(4):3086. doi: 10.3390/ijms24043086. PMID: 36834500; PMCID: PMC9959383.

2.      Govek KW, Troisi EC, Miao Z, Aubin RG, Woodhouse S, Camara PG. Single-cell transcriptomic analysis of mIHC images via antigen mapping. Sci Adv. 2021 Mar 5;7(10):eabc5464. doi: 10.1126/sciadv.abc5464. PMID: 33674303; PMCID: PMC7935366.

3.      Ptacek J, Locke D, Finck R, Cvijic ME, Li Z, Tarolli JG, Aksoy M, Sigal Y, Zhang Y, Newgren M, Finn J. Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types. Lab Invest. 2020 Aug;100(8):1111-1123. doi: 10.1038/s41374-020-0417-4. Epub 2020 Mar 23. PMID: 32203152.

4.      Lim HJ, Wang Y, Buzdin A, Li X. A practical guide for choosing an optimal spatial transcriptomics technology from seven major commercially available options. BMC Genomics. 2025 Jan 20;26(1):47. doi: 10.1186/s12864-025-11235-3. PMID: 39833687; PMCID: PMC11744898.

5.      Cilento MA, Sweeney CJ, Butler LM. Spatial transcriptomics in cancer research and potential clinical impact: a narrative review. J Cancer Res Clin Oncol. 2024 Jun 8;150(6):296. doi: 10.1007/s00432-024-05816-0. PMID: 38850363; PMCID: PMC11162383.

6.      Wang N, Hong W, Wu Y, Chen ZS, Bai M, Wang W, Zhu J. Next-generation spatial transcriptomics: unleashing the power to gear up translational oncology. MedComm (2020). 2024 Oct 6;5(10):e765. doi: 10.1002/mco2.765. PMID: 39376738; PMCID: PMC11456678.

7.      Wu K, Lin K, Li X, Yuan X, Xu P, Ni P, Xu D. Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020 Aug 4;11:1731. doi: 10.3389/fimmu.2020.01731. PMID: 32849616; PMCID: PMC7417513.

8.      Govek KW, Troisi EC, Miao Z, Aubin RG, Woodhouse S, Camara PG. Single-cell transcriptomic analysis of mIHC images via antigen mapping. Sci Adv. 2021 Mar 5;7(10):eabc5464. doi: 10.1126/sciadv.abc5464. PMID: 33674303; PMCID: PMC7935366.

9.      Jung N, Kim TK. Spatial transcriptomics in neuroscience. Exp Mol Med. 2023 Oct;55(10):2105-2115. doi: 10.1038/s12276-023-01093-y. Epub 2023 Oct 2. PMID: 37779145; PMCID: PMC10618223.

10. Li Y, Lu R, Abuduhailili X, Feng Y. Apolipoprotein E: A Potential Prognostic and Diagnostic Biomarker for Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2025 Feb 17;12:301-324. doi: 10.2147/JHC.S504078. PMID: 39991517; PMCID: PMC11844312.

11. Choe K, Pak U, Pang Y, Hao W, Yang X. Advances and Challenges in Spatial Transcriptomics for Developmental Biology. Biomolecules. 2023 Jan 12;13(1):156. doi: 10.3390/biom13010156. PMID: 36671541; PMCID: PMC9855858.